Glycolysis-activating agents for treatment or prevention of disease
AssigneeQueen Mary University of London
InventorFederica Maria Marelli-Berg
Life of this patent
Estimating the term…
Abstract
The present invention relates to glycolysis-activating agents. The present invention also relates to the treatment or prevention of diseases or medical conditions, in particular immune-related diseases or medical conditions. In particular, the present invention also relates to agents for use in the treatment or prevention of a disease or medical condition, which treatment or prevention is mediated via the trafficking of endogenous regulatory T cells (Tregs).
Claims15
A method of treating or preventing a disease or condition in a subject, said method comprising administering a glycolysis-activating agent to the subject, wherein:
- (a) said treatment or prevention is mediated via the trafficking of endogenous regulatory T cells (Tregs);
- or
- (b) said disease or medical condition is alleviated by the trafficking of endogenous regulatory T cells (Tregs) to a tissue or organ.
A method of modulating the immune response in a subject, said method comprising administering a glycolysis-activating agent to the subject, the method optionally comprising:
- (a) suppressing the immune response of the subject;
- or
- (b) suppressing or regulating an autoimmune response in the subject.
An ex vivo method of trafficking or mobilising a Treg cell comprising the step of activating glycolysis in the Treg cell by contacting the Treg cell with a glycolysis-activating agent.
A method of treating an immune mediated disease or medical condition comprising the steps of:
- a) isolating Treg cells from a subject to be treated and/or isolating Treg cells from another subject or source;
- b) expanding the Treg cells from step (a) to obtain sufficient numbers for therapy;
- c) contacting or pre-treating the Treg cells from step (b) with a GCK-activating agent;
- d) administering the Treg cells from step (c) into the subject to be treated.
An isolated, glycolytically-activated Treg cell.
Dependencies are inferred from the claim text.